Skip to main content

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Clara Carnicer Cáceres

Institutions of which they are part

Postdoctoral researcher
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Vall Hebron Institut de Recerca

Projects

Validación funcional de variantes en el genoma mitocondrial y nuclear en pacientes con patologia mitocondrial

IP: Elena García Arumí
Collaborators: Mª Jesus Melia Grimal, Clara Carnicer Cáceres, Paula Fernández Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 102850
Reference: PI19/01772
Duration: 01/01/2020 - 31/12/2023

Enfermedades minoritarias causantes de degeneración de ganglios basales en pedriatría: implemementación combinada del análisis genómico y de biomarcadores.

IP: Perez Dueñas, Belen
Collaborators: José Antonio Arranz Amo, Josefa Élida Vázquez Méndez, Alfons Macaya Ruíz, Clara Carnicer Cáceres, Mireia del Toro Riera, Ana Felipe Rucián
Funding agency: Instituto de Salud Carlos III
Funding: 196020
Reference: PI18/01319
Duration: 01/01/2019 - 31/12/2022

INTERACCIONES ENTRE IgA1 DEGALACTOSILADA Y LECTINA DE UNION A MANOSA EN ENFERMOS CON NEFROPATIA IgA: RELACION CON LA ACTIVACION DEL COMPLEMENTO PO

IP: -
Collaborators: Clara Carnicer Cáceres, Irene Agraz Pamplona
Funding agency: Instituto de Salud Carlos III
Funding: 38115
Reference: PI14/01831
Duration: 01/01/2015 - 31/03/2018

Caracterización clínica de variantes patogénicas e investigación de nuevos factores pronósticos en la nefropatía IgA

IP: -
Collaborators: Manuel Hernández González, Clara Carnicer Cáceres, Maria Teresa Salcedo Allende
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI10/01055
Duration: 01/01/2011 - 31/12/2013

Related news

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

Related professionals

Marc-Enric Fernandez Exposito

Marc-Enric Fernandez Exposito

Tècnic/a Grau Superior
Unitat legal
Direcció Jurídica
Read more
Bernat Massó Carreras

Bernat Massó Carreras

Research technician
Reconstructive Surgery of the Locomotor System
Read more
Xavier Serra Ruiz

Xavier Serra Ruiz

Research technician
Physiology and Pathophysiology of the Digestive Tract
Read more
Gemma  Duarri Llado

Gemma Duarri Llado

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.